Get the Stockscreener App
7.97
2.21%
-0.18
Immunitybio Inc stock is traded at $7.97, with a volume of 11.29M.
It is down -2.21% in the last 24 hours and up +2.44% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.15
Open:
$8.05
24h Volume:
11.29M
Relative Volume:
0.46
Market Cap:
$8.35B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.45
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-6.35%
1M Performance:
+2.44%
6M Performance:
+283.17%
1Y Performance:
+198.50%
1-Day Range:
$7.805
$8.14
1-Week Range:
$7.78
$8.69
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.97 | 8.54B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus - TechStock²
IBRX Stockholders Have Opportunity to Lead ImmunityBio, Inc. Clas - The National Law Review
IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoil - MSN
ImmunityBio secures exclusive U.S. rights to Tokyo BCG strain By Investing.com - Investing.com Australia
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio secures exclusive U.S. rights to Tokyo BCG strain - Investing.com
New deal targets decade-long bladder cancer BCG shortage in U.S. - Stock Titan
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States - Business Wire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
IBRX stock jumps after-hours: Bulls cheer 'unstoppable' global expansion amid US regulatory heat for Anktiva - MSN
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio announces partnership to expand access to Anktiva across 30 countries - MSN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - PR Newswire
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ImmunityBio stock (US45258J1025): Class action deadline nears amid FDA scrutiny - AD HOC NEWS
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - PR Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, - GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misled on Drug Efficacy: Levi & Korsinsky - PR Newswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit S - GuruFocus
Reaffirming our Commitment to Advertising Compliance - ImmunityBio
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
IBRX stock can't shake FDA delay overhang: Founder touts Saudi and Greece progress with Anktiva as bright spots - MSN
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered LossesContact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline - The Globe and Mail
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Loss - The National Law Review
IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - ChartMill
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results - simplywall.st
ImmunityBio, Inc. (NASDAQ:IBRX) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
Immunitybio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Feb 23 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Feb 23 '26 |
Sale |
10.00 |
25,000 |
250,000 |
0 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
40,650 |
0 |
320,825 |
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '26 |
Option Exercise |
0.00 |
114,329 |
0 |
29,816,081 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
4,065 |
0 |
117,548 |
| Adcock Richard | CEO & President |
Feb 22 '26 |
Option Exercise |
0.00 |
152,439 |
0 |
637,904 |
| Simon Barry J. | Director |
Feb 22 '26 |
Option Exercise |
0.00 |
15,243 |
0 |
3,096,847 |
| Simon Barry J. | Director |
Feb 23 '26 |
Sale |
10.25 |
165,000 |
1,691,102 |
2,925,821 |
| Simon Barry J. | Director |
Feb 20 '26 |
Sale |
9.25 |
10,000 |
92,500 |
3,081,604 |
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):